Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 28, 2006

Inyx to Acquire Pharmapac in Deal Valued at Over $17M

  • Inyx Pharma executed a definitive agreement to acquire Pharmapac, a contract pharmaceutical production and packaging provider in the U.K. The acquisition is expected to be completed by November 14, 2006. The purchase price is approximately $17 million in cash at closing plus $2.9 million in cash if certain milestones are met in 2007 and 2008.

    “This is another strategic acquisition for Inyx. Pharmapac is highly profitable and a strong cash generator and it has a network of complementary distribution and packaging customers,” says Jack Kachkar, M.D., chairman and CEO of Inyx.

    “The addition of Pharmapac’s dedicated packaging facility will enable Inyx to provide a dynamic secondary-packaging resource for a wide range of dosage forms needed to serve high-demand respiratory, allergy, dermatology, and topical product sectors. Pharmapac increases Inyx’ capabilities to provide innovative packaging designs for new formulations and drug delivery systems being utilized today by our clients, as well as by Inyx.”

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »